$50B+ from Skyrizi & Rinvoq
AbbVie's two drugs, Skyrizi and Rinvoq, are approaching well over $50 billion in combined revenue, rivaling the obesity drug market.
Snapshot · Bloomberg Intelligence
Microsoft and Chevron Sign 20-Year Power Deal For Texas Data Center
Explore episode
Jun 22, 2026
Where this was said
AbbVie's $10.9B All-Cash Acquisition of Apogee Therapeutics
At 10:21 · chapter starts 9:08
Sam Fazeli discusses AbbVie's bid for eczema drug developer Apogee, its $50B+ immunology revenue base, pharma's cash generation strength, and emerging frontiers in neuroscience and women's health. [1] — Sam Fazeli "The entire pharma world is chasing obesity drugs worth $100 billion. But AbbVie's two immunology drugs — Skyrizi and Rinvoq — are already a…" 10:08
$10.9 billion AbbVie deal
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash to expand its anti-inflammatory drug portfolio.
49% acquisition premium
AbbVie's offer for Apogee Therapeutics represents a roughly 49% premium to Apogee's closing price of $90.38.
AbbVie's $10.9B Apogee Bet on Eczema
AbbVie already has the biggest immunology franchise in pharma with Skyrizi and Rinvoq heading toward $50B+ in combined revenue. Buying Apogee for $10.9 billion gives it a foothold in atopic dermatitis — a massive and underserved eczema market.
You Don't Need Obesity Drugs to Win in Pharma
The entire pharma world is chasing obesity drugs worth $100 billion. But AbbVie's two immunology drugs — Skyrizi and Rinvoq — are already approaching $50 billion combined. Inflammation is a pharma goldmine that doesn't get nearly enough attention.
Why Every Major Pharma Company Can Afford Big Acquisitions
Big pharma runs at 30%+ operating margins across the board. Even Pfizer, whose stock has halved from pandemic peaks, generates enormous cash with low leverage. These are cash-rich companies, and large all-cash acquisitions are entirely within reach for almost all of them.
Pfizer share price halved from pandemic peak
Pfizer's share price has halved since pandemic peaks, yet the company still generates substantial cash flow with relatively low leverage.
Similar snapshots
Mayo Clinic radiology staff grew 55%
Despite predictions that AI would eliminate radiologists, the Mayo Clinic's radiology staff grew 55% after AI arrived at reading scans.
Radiology incomes 48% higher than a decade ago
In 2025, radiology was the second-highest paid medical specialty in America, with average incomes 48% higher than a decade ago.
Radiologists spend only 36% of time reading scans
A study across 3 hospitals found radiologists spent only 36% of their time reading scans — the part AI can do — with the rest being human judgment.
1 in 6 Americans on depression meds
Robert Greene notes that one in six Americans is on some form of drug to deal with depression, suggesting a deep societal disconnection from meaningful experience.
500 self-help techniques → 12 levers
Spencer Greenberg and Jeremy Stevenson analyzed almost 500 self-improvement techniques and found they all reduce to just 12 underlying psychological drivers.
Cold exposure: weak long-term evidence
Cold exposure has good short-term alertness benefits but the evidence base for long-term health benefits is much weaker than popularly believed.
20 habit techniques tested; almost none worked
In a randomized study of 20 habit-formation techniques run on hundreds of people, almost none of the techniques produced statistically meaningful results.
Tiny habit users stick to the FULL habit more
People given a tiny-habit fallback option (e.g. 10 squats instead of gym) were actually MORE successful at completing the full habit, not less.
Habit reflection = standout technique
The most effective habit-formation technique was 'habit reflection' — recalling a past successful habit, writing down what helped, then applying those lessons to a new habit.
